Policy briefing
October peptide policy: check the document behind the offer
Read peptide policy, Hims and Hers announcements, and the questions worth separating before a care conversation.
On October 30, 2026, the Federal Register published notice 2026-22192 (91 FR 68526), announcing a draft HHS policy for certain peptide substances during section 503A rulemaking. The draft is nonbinding and creates no rights. Publication does not mean permanent placement on the 503A bulks list; the notice supplies no separate effective date. Source 2
Begin with the question you want a document to answer. Are you checking a regulatory development, a company's intended service, or the preparation proposed for you? Make a separate space for each. This briefing puts the documents beside one another so you can keep those questions distinct. It does not inspect a pharmacy, validate a certificate, or assess whether a treatment would suit you.
Match the preparation and route
| Preparation | Route described |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral or topical. |
| Epitalon acetate | Subcutaneous or intramuscular; intermittent courses. |
| KPV acetate | Topical or oral. |
| MOTS-c acetate | Subcutaneous or intramuscular. |
| Semax free base | Intranasal. |
| TB-500 acetate | Subcutaneous or intramuscular. |
Read every condition
- Appendix A inclusion.
- Appendix B identity and route, including sequence, structure, molecular weight and formula.
- Section 510 registered source; valid COA documenting Appendix B characterization/testing results.
- Original manufacturer: FDA registration, CGMP and FD&C compliance, physical facility location on COA; FDA registered intermediaries document appropriate manufacturer and COA validation.
- Report products, serious adverse events regardless of causality, and quality issues to FDA and compounding/destination states; use MedWatch for events/quality; label patient reporting procedures; include ingredient/unit strength, original manufacturer, unique facility identifier, form/route.
- Label: “This is a compounded drug product. Not for resale.”
- Sole active ingredient: Appendix A listed.
- Oral formulations: document adequate human bioavailability for the preparation supplied.
- Only co-packaged or drug-containing delivery device: FDA 510(k) cleared syringe.
- All other FD&C requirements, including sanitation and patient specific prescriptions.
Read the status before the offer
The notice concerns the 503A setting: state-licensed pharmacies, federal facilities and licensed physicians. It describes interim enforcement discretion while rulemaking continues, not a 503B authorization. HHS can revisit the policy if safety or quality concerns arise. Source 2
FDA says compounded medicines lack FDA approval and its premarket verification of safety, effectiveness and quality. They are not approved generic medicines. A regulatory document about compounding should therefore not be presented as approval of a finished preparation. Source 4
Keep the organizations on separate lines
FDA distinguishes the compounder's setting: drugs made under section 503A's conditions are exempt from current good manufacturing practice (CGMP) requirements, while drugs compounded by 503B outsourcing facilities remain subject to them. Federal restrictions on insanitary conditions still apply in either setting. Source 4
For your own notes, give the original manufacturer and the compounder separate lines. Ask a respondent to identify which role each statement describes. An answer about one organization should not silently stand in for records about another. Keep the ten conditions above beside that exchange rather than reducing your question to whether a business has a registration number.
Read the company's verbs
Hims & Hers' October 29 announcement previews Peptides+, a forthcoming specialty. Its planned options include Sermorelin, Glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 conditional on being allowable. It describes independent providers and licensed pharmacies. Its forward-looking caution says launch timing, availability and outcomes may differ from expectations, and acknowledges limited clinical data. This is a company plan, not confirmation that those treatments are currently available or that a customer will benefit. Source 3
If you save the announcement, save your question with it: what would establish that the particular service you are asking about has actually begun? Seek a dated answer naming the offer. Keep a promised next step separate from a completed one. We have not tested enrollment, obtained a prescription, or verified dispensing for this briefing.
Prepare a document check you can finish
Choose one claim from the page you are reading. Copy its wording, record the address and date, and write what you think it means in your own words. Then ask what evidence would distinguish that interpretation from a narrower one. This makes the follow-up specific: you are asking about a named claim rather than requesting a general reassurance.
Keep the resulting answer beside the question, not in a separate folder of encouraging messages. Mark which part was answered, who answered it and what remains open. If the response names a different preparation or refers you to another organization, carry that difference forward explicitly. Do not fill an empty entry with an assumption just to make the comparison look complete.
Our earlier provider files remain separate records. This October briefing does not renew their research dates or certify their older prescribing statements. Use the related reading to recover that context, then ask for the documents that address your present question. For a treatment decision, take the unresolved clinical questions to your treating professional.
Reader questions
What should I compare when two answers sound different?
Start by checking whether they answer the same question. Write the named product, organization and date beside each answer. Circle the difference you need resolved and ask about that difference directly. A useful comparison preserves the mismatch until someone explains it; it does not turn two incomplete statements into a single confident conclusion.
What has this briefing checked?
We read the linked policy, publication notice, company announcement and FDA explanation for this dated guide. We have not examined a supplied batch, inspected a facility, assessed a patient's eligibility or independently tested a company's service. The source links let you inspect the basis of the briefing; they do not turn our reading into any of those other checks.
Sources
- Source 1Peptide policyHHS · Checked
- Source 2Notice 2026-22192Federal Register · Checked
- Source 3Expanding Safe Access to PeptidesHims & Hers · Checked
- Source 4Compounding and the FDA: Questions and AnswersFDA · Checked